New Structure-activity Relationships of N-acetamide Substituted Pyrazolopyrimidines As Pharmacological Ligands of TSPO

Overview

Journal Bioorg Med Chem Lett

Specialty Biochemistry

Date 2016 Jun 30

PMID 27353534

Citations 2

Authors

Jun Li

Michael L Schulte

Michael L Nickels

H Charles Manning

Affiliations

Soon will be listed here.

Abstract

Translocator protein (TSPO) represents an attractive target for molecular imaging and therapy due to its prevalence and critical roles played in oncology and other pathologies. Based upon our previously optimized pyrazolopyrimidine scaffold, we elucidated new structure activity relationships related to N,N-disubstitutions of the terminal acetamide on pyrazolopyrimidines and further explored the impacts of these substituents on lipophilicity and plasma protein binding. Several novel chemical probes reported here exhibited significantly increased binding affinity, suitable lipophilicity and protein binding compared with contemporary TSPO ligands. We illustrate that N,N-acetamide disubstitution affords opportunities to introduce diverse chemical moieties distal to the central pyrazolopyrimidine core, without sacrificing TSPO affinity. We anticipate that further exploration of N-acetamide substitutions may yield additional TSPO ligands capable of furthering the field of precision medicine.

Citing Articles

Development and evaluation of [C]DPA-813 and [F]DPA-814: novel TSPO PET tracers insensitive to human single nucleotide polymorphism rs6971.

Beaino W, Jm Kooijman E, Werry E, Vellinga R, Van den Hoek J, Sohler G Eur J Nucl Med Mol Imaging. 2025; .

PMID: 39907797 DOI: 10.1007/s00259-025-07109-1.

Synthesis, In Silico and In Vitro Characterization of Novel ,-Substituted Pyrazolopyrimidine Acetamide Derivatives for the 18KDa Translocator Protein (TSPO).

Park J, Wasim S, Jung J, Kim M, Lee B, Alam M Pharmaceuticals (Basel). 2023; 16(4).

PMID: 37111333 PMC: 10142799. DOI: 10.3390/ph16040576.

Insights into the medicinal chemistry of heterocycles integrated with a pyrazolo[1,5-]pyrimidine scaffold.

Hammouda M, Gaffer H, Elattar K RSC Med Chem. 2022; 13(10):1150-1196.

PMID: 36325400 PMC: 9580358. DOI: 10.1039/d2md00192f.

References

Marangos P, Patel J, Boulenger J . Characterization of peripheral-type benzodiazepine binding sites in brain using [3H]Ro 5-4864. Mol Pharmacol. 1982; 22(1):26-32. View

Selleri S, Bruni F, Costagli C, Costanzo A, Guerrini G, Ciciani G . 2-Arylpyrazolo[1,5-a]pyrimidin-3-yl acetamides. New potent and selective peripheral benzodiazepine receptor ligands. Bioorg Med Chem. 2001; 9(10):2661-71. DOI: 10.1016/s0968-0896(01)00192-4. View

Kozikowski A, Kotoula M, Ma D, Boujrad N, Tuckmantel W, Papadopoulos V . Synthesis and biology of a 7-nitro-2,1,3-benzoxadiazol-4-yl derivative of 2-phenylindole-3-acetamide: a fluorescent probe for the peripheral-type benzodiazepine receptor. J Med Chem. 1997; 40(16):2435-9. DOI: 10.1021/jm970220w. View

Le Fur G, Perrier M, Vaucher N, Imbault F, Flamier A, Benavides J . Peripheral benzodiazepine binding sites: effect of PK 11195, 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide. I. In vitro studies. Life Sci. 1983; 32(16):1839-47. DOI: 10.1016/0024-3205(83)90062-0. View

Tang D, Hight M, McKinley E, Fu A, Buck J, Smith R . Quantitative preclinical imaging of TSPO expression in glioma using N,N-diethyl-2-(2-(4-(2-18F-fluoroethoxy)phenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide. J Nucl Med. 2012; 53(2):287-94. PMC: 3391587. DOI: 10.2967/jnumed.111.095653. View

Cheung Y, Nickels M, Tang D, Buck J, Manning H . Facile synthesis of SSR180575 and discovery of 7-chloro-N,N,5-trimethyl-4-oxo-3(6-[(18)F]fluoropyridin-2-yl)-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide, a potent pyridazinoindole ligand for PET imaging of TSPO in cancer. Bioorg Med Chem Lett. 2014; 24(18):4466-4471. PMC: 4163096. DOI: 10.1016/j.bmcl.2014.07.091. View

Papadopoulos V, Baraldi M, Guilarte T, Knudsen T, Lacapere J, Lindemann P . Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci. 2006; 27(8):402-9. DOI: 10.1016/j.tips.2006.06.005. View

Buck J, McKinley E, Hight M, Fu A, Tang D, Smith R . Quantitative, preclinical PET of translocator protein expression in glioma using 18F-N-fluoroacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyaniline. J Nucl Med. 2010; 52(1):107-14. PMC: 3027353. DOI: 10.2967/jnumed.110.081703. View

James M, Fulton R, Henderson D, Eberl S, Meikle S, Thomson S . Synthesis and in vivo evaluation of a novel peripheral benzodiazepine receptor PET radioligand. Bioorg Med Chem. 2005; 13(22):6188-94. DOI: 10.1016/j.bmc.2005.06.030. View

10.

van Liempd S, Morrison D, Sysmans L, Nelis P, Mortishire-Smith R . Development and validation of a higher-throughput equilibrium dialysis assay for plasma protein binding. J Lab Autom. 2011; 16(1):56-67. DOI: 10.1016/j.jala.2010.06.002. View

11.

Tang D, McKinley E, Hight M, Uddin M, Harp J, Fu A . Synthesis and structure-activity relationships of 5,6,7-substituted pyrazolopyrimidines: discovery of a novel TSPO PET ligand for cancer imaging. J Med Chem. 2013; 56(8):3429-33. PMC: 3648642. DOI: 10.1021/jm4001874. View

12.

Kappe C . Controlled microwave heating in modern organic synthesis. Angew Chem Int Ed Engl. 2004; 43(46):6250-84. DOI: 10.1002/anie.200400655. View

13.

Batarseh A, Papadopoulos V . Regulation of translocator protein 18 kDa (TSPO) expression in health and disease states. Mol Cell Endocrinol. 2010; 327(1-2):1-12. PMC: 2922062. DOI: 10.1016/j.mce.2010.06.013. View

14.

Manning H, Goebel T, Thompson R, Price R, Lee H, Bornhop D . Targeted molecular imaging agents for cellular-scale bimodal imaging. Bioconjug Chem. 2004; 15(6):1488-95. DOI: 10.1021/bc049904q. View

15.

Tang D, Buck J, Hight M, Manning H . Microwave-assisted Organic Synthesis of a High-affinity Pyrazolo-pyrimidinyl TSPO Ligand. Tetrahedron Lett. 2010; 51(35):4595-4598. PMC: 2913893. DOI: 10.1016/j.tetlet.2010.06.074. View

16.

Manning H, Smith S, Sexton M, Haviland S, Bai M, Cederquist K . A peripheral benzodiazepine receptor targeted agent for in vitro imaging and screening. Bioconjug Chem. 2006; 17(3):735-40. DOI: 10.1021/bc060020b. View

17.

Selleri S, Gratteri P, Costagli C, Bonaccini C, Costanzo A, Melani F . Insight into 2-phenylpyrazolo[1,5-a]pyrimidin-3-yl acetamides as peripheral benzodiazepine receptor ligands: synthesis, biological evaluation and 3D-QSAR investigation. Bioorg Med Chem. 2005; 13(16):4821-34. DOI: 10.1016/j.bmc.2005.05.015. View

18.

Tang D, Nickels M, Tantawy M, Buck J, Manning H . Preclinical imaging evaluation of novel TSPO-PET ligand 2-(5,7-Diethyl-2-(4-(2-[(18)F]fluoroethoxy)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)-N,N-diethylacetamide ([ (18)F]VUIIS1008) in glioma. Mol Imaging Biol. 2014; 16(6):813-20. PMC: 4372299. DOI: 10.1007/s11307-014-0743-2. View